Cutting GLP-1 coverage may cost UVM Health more than it saves

July 15, 2026 - 21:51

The University of Vermont Health Network expects to save roughly $19 million annually by dropping GLP-1 weight loss drug coverage for its employees. But critics argue that number ignores a key question: what happens to the medical bills these patients no longer incur once the medication works?

GLP-1 drugs, like Ozempic and Wegovy, are expensive. A monthly supply can cost over $1,000. For a large employer like UVM Health, covering those prescriptions for thousands of staff members adds up fast. The network says the decision to cut coverage was a tough but necessary budget move, especially as the drugs' popularity surges.

However, health economists point out that the savings calculation may be short-sighted. These medications are proven to reduce the risk of heart attacks, strokes, and diabetes complications. When patients lose weight and improve their metabolic health, they often need fewer hospital stays, fewer surgeries, and less expensive treatments for chronic conditions. Those avoided costs are real money for a self-insured employer like UVM Health.

If the network only counts the pharmacy bill and ignores the downstream medical savings, the $19 million figure could be misleading. In fact, some analyses suggest that for every dollar spent on GLP-1 drugs, employers save two or three dollars in other medical claims within a few years. UVM Health did not release a detailed breakdown of how it arrived at its $19 million estimate, leaving many to wonder if the real net impact might be far smaller, or even negative.

The move also raises morale questions. Employees who rely on these drugs for weight-related health issues now face a choice: pay full price out of pocket, switch to less effective alternatives, or stop treatment altogether. For a healthcare organization that promotes wellness, the policy shift sends a mixed message. Whether the short-term savings will hold up under long-term scrutiny remains an open question.